Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
Granata Bio is a US-based biopharmaceutical company focused on reproductive health and fertility, in-licensing IVF medications used outside the US to develop and commercialize them in North America. Its aim is to expand therapeutic options, lower costs, and increase access to fertility treatment for patients.
2 investors
Grand River Aseptic Manufacturing (GRAM) is a contract development and manufacturing organization (CDMO) specializing in sterile fill-finish and aseptic manufacturing of injectable pharmaceutical and biologic products. It serves pharmaceutical and biotech clients across the drug product lifecycle, from development through commercial supply.
2 investors
Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options. The company is based in Basel, Switzerland, with a pipeline including Minokitug for autoimmune inflammation and GRT-002 for allergy and itch conditions.
2 investors
Grannus Therapeutics develops Hsp90 inhibitors that selectively target the beta isoform of the Hsp90 protein for cancer treatment. Its lead candidate, GRE317, is designed for single-agent anti-tumor activity and combination with therapies such as PARP inhibitors and immunotherapies, with programs advancing toward IND-enabling milestones and clinical studies.
2 investors
Greenbone Ortho develops orthopedic medical products and constantly pursues clinical innovation and new applications. The company is based in Italy and focuses on advancing orthopedic treatment solutions.
2 investors
2 investors
Grolltex manufactures single-layer graphene and graphene-based products using patented CVD and transfer technologies, serving customers in life sciences, biotech, sensing, and electronics. The company operates a U.S.-based foundry offering graphene materials and processing services with a focus on cost-effective, high-throughput production.
2 investors
Gross-Wen Technologies (GWT) develops the patented RAB algae-based system to treat municipal and industrial wastewater, recovering nutrients from the water and recycling the nutrient-rich algae into slow-release fertilizer. The company serves municipal and industrial clients seeking sustainable wastewater treatment.
2 investors
Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for bleeding and blood-related diseases, with an initial focus on platelet-inspired treatments for active bleeding and bleeding risks from trauma, surgery, thrombocytopenia, and rare bleeding disorders. Its lead technology, SynthoPlate, is a fully-synthetic hemostatic agent that acts at the injury site to amplify the body's natural clotting mechanisms.
2 investors
HanchorBio is a biotech company developing innovative immunotherapy drugs for cancer treatment through translational medicine, moving from early research to clinical applications.
2 investors
Hanimune Therapeutics develops therapeutics for food allergy prevention and tolerance support for pediatric and adult patients, drawing on immunological science and food protein research.
2 investors
Haplotype Labs develops population genetics software and polygenic risk scores with improved security, accessibility, and sophistication to enhance human healthspan. The company serves researchers, healthcare providers, and consumers seeking genetic risk assessment tools.
2 investors
Harness Therapeutics develops disease-modifying precision therapies for hard-to-treat neurodegenerative diseases through controlled modulation of CNS targets. Its pipeline targets conditions including Huntington's disease, Parkinson's disease, Alzheimer's disease, and ALS, using expertise in RNA biology and targeted protein modulation.
2 investors
2 investors
HBVtech develops a gene therapy platform intended to treat chronic infections with a single injection. Its lead program targets chronic hepatitis B (cHBV) infections, aiming for a lasting cure through one administration.
2 investors
HealthBiome is a South Korean biotech venture developing microbiome-based therapeutics targeting intractable diseases such as cancer, dementia, and metabolic disorders. The company focuses on strictly anaerobic, hard-to-culture gut microbiome strains, with capabilities in large-scale anaerobic cultivation, multi-omics analysis, and preclinical animal testing.
2 investors
Healx uses artificial intelligence to redevelop, combine, and enhance known compounds to build a pipeline of therapies for rare diseases, with an expanding focus on oncology and preventing cancer recurrence. The company runs multiple drug discovery programmes in parallel, bringing candidate treatments from prediction through clinical trials.
2 investors
HeartGenetics develops personalized genetic tests and reports for cardiovascular health, pharmacogenetics, and wellness using a DNA microchip platform and computational algorithms. The company serves healthcare providers and patients seeking genetic insights for preventive and personalized medicine.
2 investors
Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone. Its pipeline targets quarterly-dosed treatments, with a first-in-class GIP-binding antibody validated in a Phase 1 study.
2 investors
Helogen builds fully automated, AI-driven factories in orbit that produce high-value biomaterials impossible to manufacture on Earth by leveraging the microgravity environment. The company targets pharmaceutical, biotech, and health-focused industries, enabling superior product purity and carbon-positive manufacturing at unprecedented scale.
2 investors
Hememics develops FAST (Functionalized Analyte Screening Technology), an immunoassay-based screening platform that lets researchers use their own antibodies and antigens to screen antibody mini-panels in under an hour. Positioned as a faster, lower-cost alternative to ELISA, it delivers digital end-point results using a 96-well plate and a compatible reader.
2 investors
HepaTx develops stem cell-based hepatocyte therapies for liver disease treatment as an alternative to organ transplantation. The company targets niche liver disease indications including alpha-1 antitrypsin deficiency, phenylketonuria, and non-alcoholic steatohepatitis.
2 investors
HEPHAISTOS is a biopharmaceutical company developing third-generation innate immune boosters (TLR4 agonists) that convert myeloid-rich, immunotherapy-resistant tumors into immunotherapy-responsive tumors. Its lead candidate HEPHA440 targets front-line cancer therapy and is scheduled to enter clinical trials in 2027.
2 investors
Herantis Pharma is a public pharmaceutical company listed on Nasdaq First North Growth Market Finland, focused on developing therapeutic treatments.
2 investors